Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2793-2804

  Lin, Tzu yin ^a   Zhang, Hongyong ^a   Luo, Juntao ^a,c   Li, Yuanpei ^a   Gao, Tingjuan ^a   Lara, Primo N ^a,b,d   White, Ralph de Vere ^b   Lam, Kit S ^a   Pan, Chong Xian ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Bladder cancer specific peptide; Bladder urothelial carcinoma; Diagnostic imaging; Nanoparticle; Targeted therapy

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDODICARBOCYANINE DYE; ANTINEOPLASTIC AGENT; CHOLIC ACID; CYANINE DYE; DAUNORUBICIN; MACROGOL; NANOCARRIER; PACLITAXEL; PLZ 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL KILLING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL DOG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MOUSE; NANOANALYSIS; NANOCHEMISTRY; NANOIMAGING; NONHUMAN; SURFACE PROPERTY;

EID: 84864603886     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27734     Document Type: Article

References (31)

1. He X, Gao J, Gambhir SS, Cheng Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol Med. 2010;16:574-583.
2. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther. 2010;128:324-335.
3. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987;3:123-193.
4. Luo J, Xiao K, Li Y, etal. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem. 2010;21:1216-1224.
5. Xiao K, Luo J, Fowler WL, etal. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30:6006-6016.
6. Zhang H, Aina OH, Lam KS, etal. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. September 29, 2012. [Epub ahead of print.]
7. Lin TY, Zhang H, Wang S, etal. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011;10:9.
8. Tornoe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem. 2002;67:3057-3064.
9. Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol. 2009;27:284-292.
10. Schiller JH, Harrington D, Belani CP, etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
11. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127-1141.
12. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
13. Xiao K, Li Y, Luo J, etal. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32:3435-3446.
14. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-6392.
15. Modi S, Prakash Jain J, Domb AJ, Kumar N. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr Pharm Des. 2006;12:4785-4796.
16. Kim K, Kim JH, Park H, etal. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010;146:219-227.
17. Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem. 2007;7:552-558.
18. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10:2941-2952.
19. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144-158.
20. Xu L, Tang WH, Huang CC, etal. Systemic p53gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med. 2001;7:723-734.
21. Wu AM, Yazaki PJ, Tsai S, etal. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97:8495-8500.
22. Yang L, Peng XH, Wang YA, etal. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15:4722-4732.
23. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther. 2007;6:3019-3027.
24. Kirpotin DB, Drummond DC, Shao Y, etal. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740.
25. Pun SH, Tack F, Bellocq NC, etal. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3:641-650.
26. Vinall RL, Zripoll A, Wang S, Pan CX, Devere White RW. MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. Int J Cancer. June 23, 2011. [Epub ahead of print.]
27. Tanaka M, Gee JR, De La Cerda J, etal. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol. 2003;170:975-978.
28. Watanabe T, Shinohara N, Sazawa A, etal. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther. 2000;7:1575-1580.
29. Norris AM, Laing EJ, Valli VE, etal. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med. 1992;6:145-153.
30. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med. 2003;17:136-144.
31. Deborah WK, Nita WG, Dennis BD, Patty LB, Tsang LL, Lawrence TG. Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol Oncol. 2000;5:47-59.